{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:28:18Z","timestamp":1792013298295,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.berh.2022.101806","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:41:55Z","timestamp":1671608515000},"page":"101806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic alteration of the microbiota in rheumatic diseases: Hype or potential?"],"prefix":"10.1016","volume":"36","author":[{"given":"Matthew L.","family":"Stoll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"0","key":"10.1016\/j.berh.2022.101806_bib1","article-title":"Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis","volume":"2","author":"Scher","year":"2013","journal-title":"Elife"},{"key":"10.1016\/j.berh.2022.101806_bib2","series-title":"Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine","author":"Maeda","year":"2016"},{"issue":"1","key":"10.1016\/j.berh.2022.101806_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/imr.12826","article-title":"Microbial orchestra in juvenile idiopathic arthritis: sounds of disarray?","volume":"294","author":"Arvonen","year":"2020","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.berh.2022.101806_bib4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/art.38892","article-title":"Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease","volume":"67","author":"Scher","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2022.101806_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101494","article-title":"The gut microbiome in psoriasis and psoriatic arthritis","volume":"33","author":"Myers","year":"2019","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2022.101806_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-018-1510-6","article-title":"Age and fecal microbial strain-specific differences in patients with spondyloarthritis","volume":"20","author":"Stoll","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2022.101806_bib7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jgh.15222","article-title":"Systematic review and meta-analysis of the role of Faecalibacterium prausnitzii alteration in inflammatory bowel disease","volume":"36","author":"Zhao","year":"2021","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.berh.2022.101806_bib8","series-title":"Both disease activity and HLA-B27 determine gut microbiome dysbiosis in spondyloarthritis","author":"Berland","year":"2022"},{"key":"10.1016\/j.berh.2022.101806_bib9","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1016\/S2665-9913(20)30064-3","article-title":"Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study","volume":"2","author":"Wells","year":"2020","journal-title":"Lancet Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2022.101806_bib10","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1084\/jem.180.6.2359","article-title":"The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats","volume":"180","author":"Taurog","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.berh.2022.101806_bib11","series-title":"The microbiome in rheumatic diseases and infection","article-title":"Rheumatoid arthritis","author":"Stoll","year":"2018"},{"key":"10.1016\/j.berh.2022.101806_bib12","series-title":"Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria","author":"Food and Agriculture Organization and World Health Organization Expert Consultation","year":"2001"},{"issue":"4","key":"10.1016\/j.berh.2022.101806_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/03009740310003695","article-title":"Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis--a pilot study","volume":"32","author":"Hatakka","year":"2003","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2022.101806_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6882-10-1","article-title":"Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial","volume":"10","author":"Mandel","year":"2010","journal-title":"BMC Compl Alternative Med"},{"issue":"6","key":"10.1016\/j.berh.2022.101806_bib15","first-page":"CR347","article-title":"A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis","volume":"17","author":"Pineda Mde","year":"2011","journal-title":"Med Sci Mon Int Med J Exp Clin Res"},{"issue":"5","key":"10.1016\/j.berh.2022.101806_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/1756-185X.12333","article-title":"Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial","volume":"17","author":"Alipour","year":"2014","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2022.101806_bib17","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.nut.2013.09.007","article-title":"Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis","volume":"30","author":"Vaghef-Mehrabany","year":"2014","journal-title":"Nutrition"},{"issue":"9","key":"10.1016\/j.berh.2022.101806_bib18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1756-185X.12888","article-title":"Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Zamani","year":"2016","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2022.101806_bib19","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1017\/S000711451700085X","article-title":"Synbiotic supplementation and the effects on clinical and metabolic responses in patients with rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial","volume":"117","author":"Zamani","year":"2017","journal-title":"Br J Nutr"},{"key":"10.1016\/j.berh.2022.101806_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2021.111282","article-title":"Mixture of probiotics reduces inflammatory biomarkers and improves the oxidative\/nitrosative profile in people with rheumatoid arthritis","volume":"89","author":"Cannarella","year":"2021","journal-title":"Nutrition"},{"key":"10.1016\/j.berh.2022.101806_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2474-9-4","article-title":"Internet-based randomised controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthropathy","volume":"9","author":"Brophy","year":"2008","journal-title":"BMC Muscoskel Disord"},{"issue":"10","key":"10.1016\/j.berh.2022.101806_bib22","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.3899\/jrheum.100193","article-title":"Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial","volume":"37","author":"Jenks","year":"2010","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2022.101806_bib23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cei.12818","article-title":"Effect of probiotics on clinical and immune parameters in enthesitis-related arthritis category of juvenile idiopathic arthritis","volume":"185","author":"Shukla","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.berh.2022.101806_bib24","first-page":"1","article-title":"Randomized double-blinded controlled trial on the effect of synbiotic supplementation on IL-17\/IL-23 pathwayand disease activity in patients with axial spondyloarthritis","author":"Maleki","year":"2022","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"3","key":"10.1016\/j.berh.2022.101806_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2019.05.006","article-title":"A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease","volume":"49","author":"Low","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2022.101806_bib26","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/rheumatology\/kez160","article-title":"Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial","volume":"58","author":"Marighela","year":"2019","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.berh.2022.101806_bib27","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s10620-019-05830-0","article-title":"Effectiveness of Saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis","volume":"65","author":"Garcia-Collinot","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.berh.2022.101806_bib28","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/ajcn\/nqaa019","article-title":"Anti-inflammatory Diet in Rheumatoid Arthritis (ADIRA)-a randomized, controlled crossover trial indicating effects on disease activity","volume":"111","author":"Vadell","year":"2020","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.berh.2022.101806_bib29","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1017\/S0007114521002051","article-title":"Synbiotic supplementation and the effects on clinical and metabolic responses in patients with rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial - expression of concern","volume":"127","author":"Zamani","year":"2022","journal-title":"Br J Nutr"},{"issue":"2","key":"10.1016\/j.berh.2022.101806_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/nu14020354","article-title":"Efficacy of probiotics in rheumatoid arthritis and spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Sanchez","year":"2022","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.berh.2022.101806_bib31","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1007\/s10067-017-3814-3","article-title":"The therapeutic effect of probiotics on rheumatoid arthritis: a systematic review and meta-analysis of randomized control trials","volume":"36","author":"Mohammed","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2022.101806_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/J.ENG.2017.01.006","article-title":"Whether probiotic supplementation benefits rheumatoid arthritis patients: a systematic review and meta-analysis","volume":"3","author":"Pan","year":"2017","journal-title":"Engineering"},{"issue":"1","key":"10.1016\/j.berh.2022.101806_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10787-017-0436-y","article-title":"The efficacy of probiotic supplementation in rheumatoid arthritis: a meta-analysis of randomized, controlled trials","volume":"26","author":"Aqaeinezhad Rudbane","year":"2018","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.berh.2022.101806_bib34","first-page":"233","article-title":"Probiotics in spondyloarthropathy associated with ulcerative colitis: a pilot study","volume":"13","author":"Sanges","year":"2009","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.berh.2022.101806_bib35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.12659\/MST.895438","article-title":"Beneficial effect of probiotics administration in inflammatory bowel disease and related spondyloarthropathy: a prospective study","volume":"56","author":"Tomasello","year":"2015","journal-title":"Medical Science Technology"},{"key":"10.1016\/j.berh.2022.101806_bib36","series-title":"Development and validation of the juvenile spondyloarthritis disease flare (JSpAflare) measure: ascertaining flare in patients with inactive disease","author":"Weiss","year":"2021"},{"issue":"9","key":"10.1016\/j.berh.2022.101806_bib37","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.24730","article-title":"Reliability and validity of the university of California, Los Angeles Scleroderma clinical trial Consortium gastrointestinal tract instrument","volume":"61","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2022.101806_bib38","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/cei.12900","article-title":"Gut microbiome in children with enthesitis-related arthritis in a developing country and the effect of probiotic administration","volume":"187","author":"Aggarwal","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"10.1016\/j.berh.2022.101806_bib39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/annrheumdis-2018-214856","article-title":"Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal","volume":"78","author":"Azzouz","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2022.101806_bib40","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/s41467-020-15857-x","article-title":"CD8(+) regulatory T cells are critical in prevention of autoimmune-mediated diabetes","volume":"11","author":"Shimokawa","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.berh.2022.101806_bib41","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.12998\/wjcc.v8.i8.1361","article-title":"Probiotic mixture VSL#3: an overview of basic and clinical studies in chronic diseases","volume":"8","author":"Cheng","year":"2020","journal-title":"World J Clin Cases"},{"issue":"6","key":"10.1016\/j.berh.2022.101806_bib42","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.cell.2018.08.041","article-title":"Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features","volume":"174","author":"Zmora","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.berh.2022.101806_bib43","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.amjms.2018.08.010","article-title":"Current evidence in delivery and therapeutic uses of fecal microbiota transplantation in human diseases-Clostridium difficile disease and beyond","volume":"356","author":"Stripling","year":"2018","journal-title":"Am J Med Sci"},{"issue":"308","key":"10.1016\/j.berh.2022.101806_bib44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/BF02956866","article-title":"Implantation of B. coli into the human intestine","author":"Dalton","year":"1951","journal-title":"Ir J Med Sci"},{"issue":"2","key":"10.1016\/j.berh.2022.101806_bib45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/lam.13486","article-title":"Effectiveness of fecal microbiota transplant for the treatment of Clostridioides difficile diarrhea: a systematic review and meta-analysis","volume":"73","author":"Pomares Bascunana","year":"2021","journal-title":"Lett Appl Microbiol"},{"issue":"10","key":"10.1016\/j.berh.2022.101806_bib46","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1097\/MIB.0000000000000908","article-title":"Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease","volume":"22","author":"Fischer","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.berh.2022.101806_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8266793","article-title":"A systematic review and meta-analysis of randomized controlled trials of fecal microbiota transplantation for the treatment of inflammatory bowel disease","volume":"2022","author":"Tan","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"issue":"5","key":"10.1016\/j.berh.2022.101806_bib48","doi-asserted-by":"crossref","first-page":"e0232739","DOI":"10.1371\/journal.pone.0232739","article-title":"Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial","volume":"15","author":"Fretheim","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.berh.2022.101806_bib49","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1136\/annrheumdis-2020-219511","article-title":"Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial","volume":"80","author":"Kragsnaes","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101806_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102844","article-title":"Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: an EXPLORER trial","volume":"130","author":"Huang","year":"2022","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.berh.2022.101806_bib51","doi-asserted-by":"crossref","first-page":"e048541","DOI":"10.1136\/bmjopen-2020-048541","article-title":"Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial","volume":"11","author":"Hoffmann-Vold","year":"2021","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.berh.2022.101806_bib52","doi-asserted-by":"crossref","first-page":"e019231","DOI":"10.1136\/bmjopen-2017-019231","article-title":"Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial","volume":"8","author":"Kragsnaes","year":"2018","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.berh.2022.101806_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10050959","article-title":"Repeated fecal microbial transplantations and antibiotic pre-treatment are linked to improved clinical response and remission in inflammatory bowel disease: a systematic review and pooled proportion meta-analysis","volume":"10","author":"Mocanu","year":"2021","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.berh.2022.101806_bib54","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00384-020-03599-7","article-title":"Clinical remission of ulcerative colitis after different modes of faecal microbiota transplantation: a meta-analysis","volume":"35","author":"Tang","year":"2020","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"10.1016\/j.berh.2022.101806_bib55","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1309\/LMCI95M0TWPDZKOD","article-title":"Fecal microbiota transplant protocol for clostridium difficile infection","volume":"46","author":"Tauxe","year":"2015","journal-title":"Lab Med"},{"issue":"21","key":"10.1016\/j.berh.2022.101806_bib56","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.berh.2022.101806_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10122696","article-title":"Isolation of viable SARS-CoV-2 virus from feces of an immunocompromised patient suggesting a possible fecal mode of transmission","volume":"10","author":"Dergham","year":"2021","journal-title":"J Clin Med"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694222000651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694222000651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:23:41Z","timestamp":1761499421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694222000651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1521694222000651"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2022.101806","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic alteration of the microbiota in rheumatic diseases: Hype or potential?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2022.101806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101806"}}